Skip to main content

Table 3 Short-term lipid profile alteration among statin plus ezetimibe plus evolocumab/statin/statin plus ezetimibe lipid-lowering strategies in AMI patients after PSM adjustment

From: In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

 

Statin

Statin

+Ezetimibe

Statin + Ezetimibe + Evolocumab

p1

p2

LDL (mmol/L)

Admission

3.59 ± 0.95

3.82 ± 1.20

3.90 ± 1.45

0.060

0.666

Follow-up(1 m)

1.96 ± 0.49

2.04 ± 0.81

1.43 ± 1.06

0.001

0.001

Follow-up(3 m)

2.06 ± 0.42

2.37 ± 1.13

1.40 ± 0.50

< 0.001

< 0.001

TG (mmol/L)

Admission

2.08 ± 1.12

1.92 ± 1.04

1.93 ± 1.01

0.311

0.948

Follow-up(1 m)

1.72 ± 0.71

1.58 ± 0.68

1.50 ± 0.72

0.148

0.539

Follow-up(3 m)

1.53 ± 0.64

1.82 ± 0.74

1.74 ± 1.17

0.534

0.796

HDL (mmol/L)

Admission

0.98 ± 0.24

1.01 ± 0.22

1.00 ± 0.23

0.472

0.818

Follow-up(1 m)

0.99 ± 0.24

0.99 ± 0.21

0.94 ± 0.21

0.253

0.176

Follow-up(3 m)

1.03 ± 0.29

1.00 ± 0.27

0.95 ± 0.18

0.316

0.491

ApoA (g/L)

Admission

1.09 ± 0.19

1.11 ± 0.20

1.09 ± 0.21

0.877

0.456

Follow-up(1 m)

1.15 ± 0.20

1.14 ± 0.19

1.10 ± 0.18

0.850

0.336

Follow-up(3 m)

1.11 ± 0.16

1.15 ± 0.23

1.12 ± 0.14

0.525

0.606

ApoB (g/L)

Admission

1.16 ± 0.29

1.15 ± 0.24

1.16 ± 0.29

0.269

0.730

Follow-up(1 m)

0.75 ± 0.17

0.76 ± 0.20

0.59 ± 0.29

0.004

0.001

Follow-up(3 m)

0.80 ± 0.13

0.83 ± 0.29

0.61 ± 0.20

0.008

0.010

ApoE (mg/L)

Admission

46.68 ± 19.88

46.90 ± 21.08

46.68 ± 19.88

0.825

0.939

Follow-up(1 m)

31.00 ± 8.62

36.77 ± 16.37

28.92 ± 13.96

0.573

0.061

Follow-up(3 m)

37.91 ± 10.10

34.56 ± 14.43

30.26 ± 14.06

0.265

0.466

LP(a) (mg/L)

Admission

331.77

375.71

433.87

0.982

0.248

Follow-up(1 m)

450.00

283.66

271.18

0.587

0.851

Follow-up(3 m)

435.08

427.27

595.43

0.502

0.332

TCDL (mmol/L)

Admission

5.55 ± 1.14

5.72 ± 1.30

5.79 ± 1.42

0.181

0.739

Follow-up(1 m)

3.52 ± 0.65

3.55 ± 0.89

2.82 ± 1.18

< 0.001

< 0.001

Follow-up(3 m)

3.65 ± 0.74

3.93 ± 1.39

2.97 ± 0.64

0.009

0.003

  1. Data are shown as the mean ± SD, median or n (%). p1, Statin plus ezetimibe plus evolocumab vs. statin; p2, Statin plus ezetimibe plus evolocumab vs. statin plus ezetimibe. For statistical analysis, one-way ANOVA followed by Sidak’s multiple comparison test was applied
  2. TG Triglyceride, LDL Low-density lipoprotein, HDL High-density lipoprotein, ApoA apolipoprotein A, ApoB Apolipoprotein B, ApoE Apolipoprotein E, TCDL Total cholesterol lipoprotein, Lp(a) Lipoprotein(a)